summary recent updatescdc collaborating food drug administration ( fda ) state local health departments investigate multistate outbreak extensively drug-resistant strain pseudomonas aeruginosa . outbreak strain , carbapenem-resistant pseudomonas aeruginosa verona integron-mediated metallo-β-lactamase guiana extended-spectrum-β-lactamase ( vim-ges-crpa ) , never reported united states prior outbreak . outbreak associated multiple types infections , including eye infections . investigation date identified artificial tears common exposure many patients .time , cdc fda recommend clinicians patients stop using ezricare delsam pharma ’ artificial tears products pending additional guidance cdc fda .clinicians : please report carbapenem-resistant pseudomonas aeruginosa ( crpa ) ocular specimen vim-crpa specimen source collection dates since january 1 , 2022 , local state health department ’ healthcare-associated infections contact email haioutbreak @ cdc.gov assistance submitting specimens . ask clinical laboratories save isolates characterization public health laboratories .current updatemarch 14 , 2023 , cdc , partnership state local health departments , identified 68 patients 16 states ( ca , co , ct , fl , il , nc , nj , nm , ny , nv , pa , sd , tx , ut , wa , wi ) vim-ges-crpa , rare strain extensively drug-resistant p. aeruginosa . thirty-seven patients linked four healthcare facility clusters . three people died 8 reports vision loss 4 reports enucleation ( surgical removal eyeball ) . dates specimen collection may 2022 february 2023. isolates identified clinical cultures sputum bronchial wash ( 15 ) , cornea ( 17 ) , urine ( 10 ) , nonsterile sources ( 4 ) , blood ( 2 ) , rectal swabs ( 26 ) collected surveillance ; patients specimens collected one anatomic site .patients reported using artificial tears . patients reported 10 different brands artificial tears patients used multiple brands . ezricare artificial tears , preservative-free , over-the-counter product packaged multidose bottles , brand commonly reported . common artificial tears product identified across four healthcare facility clusters . laboratory testing cdc identified presence vim-ges-crpa opened ezricare bottles multiple lots ; bottles collected patients without eye infections two states . vim-ges-crpa recovered opened products match outbreak strain . testing unopened bottles ezricare artificial tears ongoing assist evaluating whether contamination may occurred manufacturing . patients healthcare providers immediately stop use ezricare artificial tears pending additional information guidance cdc fda .patient informationpatients stop using ezricare delsam pharma ’ artificial tears pending additional information guidance cdc fda . patients advised use ezricare delsam pharma ’ artificial tears healthcare provider , follow healthcare provider recommendations alternative treatment options .patients used ezricare delsam pharma ’ artificial tears signs symptoms eye infection seek medical care immediately . time , recommendation testing patients used product experiencing signs symptoms infection .infections caused strain carbapenem-resistant p. aeruginosa produces verona integron-encoded metallo-β-lactamase ( vim ) guiana-extended spectrum-β-lactamase ( ges ) . isolates p. aeruginosa sequence type ( st ) 1203 harbor blavim-80 blages-9 , combination previously identified united states .vim-ges-crpa isolates associated outbreak extensively drug-resistant ( xdr ) . isolates underwent testing public health laboratories susceptible cefepime , ceftazidime , piperacillin-tazobactam , aztreonam , carbapenems , ceftazidime-avibactam , ceftolozane-tazobactam , fluoroquinolones , polymyxins , amikacin , gentamicin , tobramycin . subset 5 isolates underwent antimicrobial susceptibility testing cefiderocol susceptible agent . subset isolates also mics aztreonam-avibactam ranging 4 – 16 μg/ml , clinical breakpoints established antimicrobial agent combination . susceptibility testing combination inform clinical decision making available cdc – refer cdc test directory .bacteriophage ( phage ) activity outbreak strain identified university california san diego ’ center innovative phage applications therapeutics ( ipath ) . clinicians interested phage potential treatment option contact ipath ipath @ health.ucsd.edu .clinician informationfacilities and/or providers discontinue use ezricare delsam pharma ’ artificial tears instruct patients currently using ezricare delsam pharma ’ artificial tears stop using product pending additional guidance cdc fda . facilities and/or providers already administered ezricare delsam pharma ’ artificial tears patients monitor signs symptoms infection perform culture antimicrobial susceptibility testing clinically indicated . healthcare providers treating patients keratitis endophthalmitis ask patients used ezricare delsam pharma ’ artificial tears .based susceptibility information isolates collected part investigation , strain p. aeruginosa susceptible cefepime , ceftazidime , piperacillin-tazobactam , aztreonam , carbapenems , ceftazidime-avibactam ceftolozane-tazobactam , fluoroquinolones , polymyxins , amikacin , gentamicin , tobramycin . subset 3 isolates underwent antimicrobial susceptibility testing cefiderocol clinical laboratories cdc susceptible agent . healthcare providers treating vim-ges-crpa infections consult specialist knowledgeable treatment antibiotic-resistant bacteria determine best treatment option .healthcare providers caring patients vim-producing p. aeruginosa follow infection control recommendations listed prevent transmission patients , bacteria potential spread rapidly healthcare settings .new vim-crpa identified inpatient long-term care settings :work clinical laboratory antimicrobial resistance laboratory network characterize isolate determine whether matches outbreak strain . facilities providers report crpa ocular specimen vim-crpa specimen source collection dates since january 1 , 2022 , local state public health departments ask clinical laboratories save isolates characterization public health laboratories .perform colonization screening healthcare contacts patients vim-crpaperform laboratory lookbacks crpaconduct prospective surveillance new cases crpa , submit isolates public health laboratories carbapenem resistance mechanism testingplace patients infected colonized vim-crpa admitted acute care settings isolation use contact precautions . residents skilled nursing facilities infected colonized vim-crpa , use enhanced barrier precautions resident indication contact precautions .clinical laboratory informationclinical laboratories identify p. aeruginosa resistant imipenem meropenem encouraged perform carbapenem resistance mechanism testing . isolates may also submitted antimicrobial resistance laboratory network mechanism testing . laboratories wishing apply specific definition identifying isolates might related cluster mechanism testing could limit testing crpa also resistant cefepime , ceftazidime , ( tested ) ceftazidime-avibactam ceftolozane-tazobactam .cdc.gov privacy settingstake privacy seriously . review change way collect information .performance cookies checkboxcookies allow us count visits traffic sources measure improve performance site . help us know pages least popular see visitors move around site . information cookies collect aggregated therefore anonymous . allow cookies know visited site , able monitor performance .functional cookies checkboxcookies used make website functionality relevant . cookies perform functions like remembering presentation options choices , cases , delivery web content based self-identified area interests .campaign cookies checkboxcookies used track effectiveness cdc public health campaigns clickthrough data .social media cookies checkboxcookies used enable share pages content find interesting cdc.gov third party social networking websites . cookies may also used advertising purposes third parties .